Bao Jianhua, the controlling shareholder of Jiangxi Fushine Pharmaceutical, has proposed a 2026 interim dividend of 0.5 yuan in cash per 10 shares before tax, with no bonus shares or conversion of capital reserve into share capital. Bao Jianhua, who also serves as the company's actual controller, chairman, and general manager, has pledged to vote in favor at the relevant meeting. The proposal still requires approval by the board of directors before implementation, following a prior shareholder meeting authorization for the board to formulate and execute the 2026 interim profit distribution plan. If the share capital changes before implementation, the total distribution amount will be adjusted based on the same distribution ratio.
Jiangxi Fushine Pharmaceutical Co LtdControlling shareholder proposes a cash dividend, which is a positive capital return event.